Comparative Pharmacology
Head-to-head clinical analysis: HYDELTRASOL versus TRIACET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDELTRASOL versus TRIACET.
HYDELTRASOL vs TRIACET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory and immunosuppressive properties; suppresses multiple inflammatory cytokines and induces lipocortin synthesis.
Triacetin is a triester of glycerol and acetic acid. Its exact mechanism of action is not fully understood, but it exhibits antifungal activity by disrupting fungal cell membrane integrity and inhibiting fungal growth.
Intravenous: Initial dose 100-250 mg, then repeat every 10-30 minutes as needed. Intramuscular: 100-250 mg every 10-30 minutes. Intra-articular: 10-40 mg per joint every 1-2 weeks.
0.5-1 mg orally three times daily; maximum dose 4 mg/day.
None Documented
None Documented
Terminal half-life ~2-3 hours; clinically, adrenal suppression may persist >24h.
Terminal elimination half-life is approximately 3.5–4 hours in adults with normal renal function; may be prolonged (up to 6–8 hours) in patients with hepatic impairment.
Renally eliminated: ~80% as metabolites, <10% unchanged. Biliary/fecal: minor.
Renal, unchanged drug: <1% of dose; metabolites: approximately 20% in urine, remainder in feces via biliary elimination.
Category C
Category C
Corticosteroid
Corticosteroid